Item 8.01. Other Events.

Pursuant to the terms of the Purchase Agreement dated November 27, 2019 by and among Aravive, Inc. (the "Company") and Piper Jaffray & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (the "Underwriters"), the Underwriters were granted an over-allotment option to purchase up to an additional 500,000 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), in connection with the previously announced public offering. On November 27, 2019, the Underwriters partially exercised such option with respect to 300,000 shares of the Company's Common Stock (the "Option Shares").

On December 2, 2019, the Company closed the public offering including the sale of the Option Shares. After giving effect to the partial exercise of the over-allotment option, the total number of shares of Common Stock sold by the Company in the public offering was 3,633,334 shares of Common Stock and total gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were approximately $27.25 million.

In addition, the Company will be making several investor presentations over the next several weeks, including investor presentations at the 2019 Piper Jaffray Healthcare Conference to be held on Wednesday, December 4, 2019 in New York, New York. In connection with the presentations, the Company intends to discuss the investor presentation attached as Exhibit 99.1 hereto, which is incorporated herein by reference.

The investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the investor presentation are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise information included in this Current Report on Form 8-K or the investor presentation attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:






      Exhibit
      Number    Description

      99.1        Aravive, Inc. Investor Presentation dated December 2019

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses